激素性骨坏死骨质丢失与骨保护蛋白表达的相关研究

被引：8

作者：

王岩

迟志永

韩纲

机构：

[1] 解放军总医院骨科研究所,解放军二一一医院骨科,解放军总医院骨科研究所北京,北京

来源：

中华外科杂志 | 2002年 / 07期

关键词：

骨坏死; 糖皮质激素类; 骨保护蛋白;

D O I：

暂无

中图分类号：

R681 [骨骼疾病];

学科分类号：

1002 ; 100210 ;

摘要：

目的　探讨在激素性骨坏死的病程中 ,股骨不同部位骨保护蛋白 /破骨细胞形成抑制因子 (OPG/OCIF)的表达情况 ,与局部骨质丢失是否存在着相关性。　方法　 31只新西兰白兔复制Yamamoto激素性骨坏死模型 ,内毒素和甲基强地松龙给药结束 3d后存活 2 4只 ;随机选 4只作为对照组 ,其余随机分为 4个不同时间组 ,每组 5只 ;按照不同时间组处死动物 ,进行股骨的骨密度值测量、病理切片H E染色和茜素红染色病理及OPG/OCIF组织化学染色 ,并进行图像处理和统计分析。结果　在激素性骨坏死早期 ,给药后 2周股骨的OPG/OCIF表达明显降低 (P <0 0 1) ,同时局部骨髓内出现了大量的破骨细胞 ;继而出现明显的骨质丢失 (从 0 375± 0 0 37、0 2 97± 0 0 2 2降至 0 173±0 0 2 4、0 183± 0 0 6 1,P <0 .0 5 )。　结论　糖皮质激素可抑制骨骼局部OPG/OCIF的表达 ,从而促进了破骨细胞分化与活性 ,加剧激素性坏死局部的骨质丢失。

引用

页码：57 / 60+87

页数：5

共 20 条

[1]

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells. Wong BR,Jaerang Rho,Arron J,et al. Journal of Biological Chemistry . 1997

[2]

Bone[P]. BIRL JOSEPH J.中国专利:US2436283A,1948-02-17

[3]

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogensis. Kong YY,Yoshida H,Sarosi I,et al. Nature . 1999

[4]

Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocoticoid-induced osteoporosis. Hofbauer LC,Gorl F,Riggs BL,et al. The Journal of Endocrinology . 1999

[5]

Inhibition of osteoblastogenesis and promotion apoptosis of osteoblasts and osteocytes by glucocoticoids. Weinstein RS,Jilka RL,Parfitt AM,et al. The Journal of Clinical Investigation . 1998

[6]

Current ooncepts review nontraumatic avascular necrosis of the femoral head. Mont MA,Hungerford DS,Maryland B. Journal of Bone and Joint Surgery British Volume . 1995

[7]

Osetoprotegerin: a novel secreted protein involved in the regulation of bone density. Simonet WS,Lacey DL,Cunstan CR,et al. Cell . 1997

[8]

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Mizuno A,Amizuka N,Irie K,et al. Biochemical and Biophysical Research Communications . 1998

[9]

Bone[P]. BIRL JOSEPH J.中国专利:US2436283A,1948-02-17

[10]

Identity of osteoclastogenesis inhibitory factor ( OCIF ) and osteoprotegerin( OPG ).a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Yasuda H,Shima N,Nakagawa N,et al. The Journal of Endocrinology . 1998

← 1 2 →